Pyrotech (Beijing) Biotechnology Co. Ltd. has identified gasdermin-E (GSDME) inhibitors reported to be useful for the treatment of genetic diseases, cancer, viral infection, age-related macular degeneration, autoimmune diseases, neurological disorders, renal disorders and cancer therapy-associated disorders.